Potential New Therapeutic Targets for Pathological Pruritus

• Kuraishi Yasushi

  Laboratory of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama

抄録

Very few approved medications are indicated for the treatment of pruritus, and drug development for pruritic diseases is awaited. During the past two decades, progress has been made in understanding the molecular basis of the physiology and pathophysiology of pruritus. Newly identified potential targets for pathological pruritus include receptors (histamine H₄ receptor, leukotriene B₄ receptors, interleukin-31 receptor A, bombesin BB₂ receptor, toll-like receptor 3, α-adrenoceptor, and opioid μ- and κ-receptors), channels (transient receptor potential (TRP) V3 and TRPA1 channels), and enzymes (histidine decarboxylase, sphingomyelin glucosylceramide deacylase, 5-lipoxygenase, leukotriene A₄ hydrolase, and autotaxin). The development of specific, effective blockers and agonists/antagonists of these targets is awaited.

収録刊行物

• Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ

  Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ 36 (8), 1228-1234, 2013

  公益社団法人 日本薬学会

キーワード

• pruritic disease
• itch mediator
• keratinocyte
• primary sensory neuron
• dorsal horn neuron
• itch inhibitory system

詳細情報

• CRID: 1390282679610402944
• NII論文ID: 130003361502
• NII書誌ID: AA10885497
• DOI: 10.1248/bpb.b13-00343
• COI: 1:STN:280:DC%2BC3sflslWmtg%3D%3D
• ISSN: 13475215
• ISSN: 09186158
• ISSN: http://id.crossref.org/issn/09186158
• NDL書誌ID: 024715739
• PubMed: 23902965
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I024715739
• Web Site: https://www.jstage.jst.go.jp/article/bpb/36/8/36_b13-00343/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2014095505
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• 抄録ライセンスフラグ: 使用不可